to a limited capacity to activate the classical complement pathway [2, 3] . Thus, until 8 recently, it was believed that IgG4 plays only a limited role in immune activation [3] . As IgG4-RD when there is an abundance of IgG4+ plasma cells in a biopsy specimen.
17
Some morphologic findings such as obliterative phlebitis are considered to be rather 18 more specific to IgG4-RD than to cancer, but existing evidence supporting this idea seems weak [10] . Serum IgG4 concentration is a helpful laboratory finding to 1 differentiate IgG4-RD and cancer, but it is not always elevated in patients with 2 IgG4-RD, while it can be elevated in cancer patients without IgG4-RD [4, 8] . In addition, 3 clinicians must keep in mind the possibility of synchronous cancer and IgG4- RD [11] .
4
In this study, we identified cases of lung cancer with stromal IgG4+ plasma cell 5 infiltration using tissue microarray (TMA). We analyzed the clinicopathologic 6 characteristics of these cases to investigate the relevance of lung cancer and IgG4+ 7 plasma cells. authors (A.Y. and S.S.) basically using the approach described by Kononen et al. [12] .
16
Briefly, the most morphologically representative region of the tumor was selected on a 17 hematoxylin and eosin (H&E)-stained slide. Then, a tissue core of 2 mm in diameter 18 was punched out from each donor tumor block using a thin-walled stainless steel needle for TMA construction (Azumaya, Tokyo, Japan), and arrayed in a recipient 1 paraffin block. Small cell carcinomas, recurrent carcinomas, carcinomas with 2 neoadjuvant chemotherapy and cases with multiple carcinomas (both synchronous 3 and metachronous) were excluded from this study, but were established in TMA for 4 another study (n=45). TMA cores that were not completely enclosed on the sections or did not include 8 viable tumor on the sections were excluded from this study (n=24). As a result, 294 9 primary non-small cell lung carcinomas (NSCLC) were extracted. The median 10 follow-up period of patients was 1748 days (range: 7-3805).
11
The 294 lung cancers consisted of 233 adenocarcinomas (79.3%), 52 squamous 12 cell carcinomas (17.7%) and 9 other NSCLC (3.1%) (6 large cell carcinomas, 2 In adenocarcinomas, mutation analysis of EGFR, KRAS and p53 was performed in 3 213 cases, 213 cases and 129 cases, respectively, and the mutation was confirmed in 4 102 cases (47.9%), 23 cases (10.8%) and 31 cases (24.0%), respectively. 
12
The median number of original tumor slides observed per case was 3 (range: 1-9) In comparison of these 6 cases and the other 29 IgG4+ cell-enriched cases, no 11 statistically significant difference was obtained in any parameters shown in Table 1,   12 except the IgG4/IgG ratio in the TMA core (median: 0.28 vs. 0.12, p=0.0062).
13
Additionally, the numbers of cases with obliterative phlebitis/arteritis and increased 14 number of eosinophils in these 2 groups did not differ significantly (83.3% vs. 100%, 15 p=0.1714, and 16.7% vs. 6.9%, p=0.4417, respectively).
17

Discussion
18
IgG4+ plasma cell infiltration in cancer and its relevance to IgG4-RD have been a matter of debate in the field of practical medicine [4] [5] [6] [7] [8] [9] . Since chronic inflammation is 1 associated with a risk of cancer development, it could be hypothesized that IgG4-RD 2 is a source of carcinoma [11, 18] . In our series, however, the idea that the patients with 3 IgG4+ cell-enriched tumor had lung IgG4-RD seems unlikely for two main reasons. conditions. In the pericancerous fibrous stroma of our IgG4+ cell-enriched cancers, 17 even obliterative phlebitis/arteritis, the histological finding of which is believed to be 18 quite specific to lung IgG4-RD, was observed in most of the cases. Pathologists Table 2 . Logistic regression analysis for estimation of significant factors related to 6 >20/HPF intra-tumoral IgG4+ plasma cell infiltration. Table 3 Figure legends (A) Case 2, solid predominant G3 adenocarcinoma (×20).
10
(B) Higher-magnification image of boxed area in (A) (×100).
11
(C) Intratumoral obliterative phlebitis (×100).
12
(D) >50/HPF IgG4+ plasma cells in the cancer stroma (×200).
13
(E) IgG immunostain at the same area as in (D), with IgG4/IgG ratio >40% (×200). 
